NEW ORLEANS, LA — Early intravenous treatment with a synthetic natriuretic peptide decongested patients with acute decompensated heart failure (ADHF) and made them feel better in the first 48 ...

The negative findings of the RELAX-AHF-2 trial, which tested serelaxin, a recombinant form of human relaxin-2, for the treatment of patients with acute heart failure (AHF), are now published. The ...

Dublin, March 01, 2024 (GLOBE NEWSWIRE) -- The "Acute Heart Failure (AHF) Therapeutics: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. Global Acute ...

Diagnosed prevalent cases of Chronic Heart Failure (CHF) in the 8MM (US, France, Germany, Italy, Spain, UK, Japan and China) are projected to increase from 26.8 million in 2018 to 32.2 million in ...

RELAX-AHF had co-primary endpoints. For the first primary endpoint, dyspnea relief through day 5 (as measured by the visual analog scale area under the curve), serelaxin was associated with a ...

The successful management of patients with acute heart failure (AHF) involves early diagnosis, rapid identification of underlying causes, and immediate implementation of effective therapies. In ...